Table 1. The relationship between clinicopathological characteristics and serum biomarkers concentrations.
n | CA125 | P v | CA15-3 | P v | CRP | P v | D-D | P v | PLR | P v | NLR | P v | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(U/ml) | (U/ml) | (mg/l) | (mg/l) | |||||||||||
Age | ||||||||||||||
<50 | 98 | 23.82 | 0.491 | 12.92 | 0.336 | 1.13 | 0.002 | 0.55 | 0.286 | 147.64 | 0.001 | 2 | 0.257 | |
(14.08–46.81) | (9.14–19.89) | (0.46–2.89) | (0.40–0.90) | (113.36–208.92) | (1.52–2.74) | |||||||||
≥50 | 184 | 21.11 | 12.19 | 2.17 | 0.6 | 125.1 | 1.83 | |||||||
(14.07–39.90) | (8.88–17.71) | (0.72–6.19) | (0.40–1.00) | (99.13–165.96) | (1.38–2.69) | |||||||||
Type | ||||||||||||||
Ⅰ | 254 | 132.18 | 0.708 | 21.67 | 0.787 | 6.42 | <0.001 | 1.34 | 0.349 | 148.87 | 0.008 | 2.29 | <0.001 | |
(41.11–223.23) | (14.04–29.31) | (3.59–9.34) | (0.45–2.23) | (140.15–157.96) | (2.11–2.46) | |||||||||
Ⅱ | 28 | 79.55 | 24.91 | 33.62 | 2.65 | 191.45 | 3.88 | |||||||
(35.68–123.28) | (7.81–42.01) | (13.79–53.46) | (1.22–4.08) | (137.34–245.57) | (2.51–5.25) | |||||||||
FiGO | ||||||||||||||
Ⅰ | 152 | 18.73 | <0.001 | 10.97 | <0.001 | 1.33 | 0.003 | 0.5 | <0.001 | 126.47 | 0.365 | 1.8 | 0.054 | |
(13.31–25.62) | (7.80–15.59) | (0.54–4.20) | (0.30–0.73) | (106.33–167.91) | (1.37–2.46) | |||||||||
Ⅱ | 58 | 25.53 | 12.37 | 1.33 | 0.6 | 129.33 | 1.9 | |||||||
(15.93–46.99) | (9.37–19.35) | (0.58–4.70) | (0.45–0.90) | (99.03–200.59) | (1.46–2.88) | |||||||||
Ⅲ | 61 | 44.41 | 15.99 | 3.07 | 0.9 | 139.07 | 2.08 | |||||||
(20.65–72.30) | (10.84–29.3) | (0.82–10.43) | (0.50–1.70) | (104.76–185.46) | (1.52–3.47) | |||||||||
Ⅳ | 11 | 93.19 | 27.93 | 3.17 | 1.4 | 155 | 2.84 | |||||||
(57.93–386.90) | (10.27–43.3) | (2.28–29.68) | (0.65–2.45) | (111.20–255.14) | (1.60–3.20) | |||||||||
Grade | ||||||||||||||
G1 | 69 | 17.75 | 0.001 | 11.16 | 0.003 | 1.11 | 0.011 | 0.5 | <0.001 | 145 | 0.124 | 2.1 | 0.126 | |
(13.22–23.01) | (7.45–15.21) | (0.45–3.27) | (0.30–0.90) | (114.94–195.72) | (1.30–2.55) | |||||||||
G2 | 145 | 25.08 | 13.07 | 1.7 | 0.55 | 129.5 | 1.76 | |||||||
(13.73–44.66) | (9.25–19.01) | (0.68–4.83) | (0.40–0.80) | (101.95–167.49) | (1.44–2.60) | |||||||||
G3 | 68 | 26.07 | 13.82 | 2.67 | 0.9 | 122.73 | 2.18 | |||||||
(15.75–62.43) | (9.70–24.82) | (0.81–12.19) | (0.50–1.70) | (101.09–205.83) | (1.49–3.32) | |||||||||
Metas. | ||||||||||||||
Yes | 14 | 20.51 | 0.689 | 14.26 | 0.97 | 4.96 | 0.019 | 1 | 0.021 | 138.71 | 0.522 | 2.3 | 0.231 | |
(11.86–59.16) | (7.28–23.54) | (1.05–48.76) | (0.65–1.73) | (108.04–243.000) | (1.40–4.63) | |||||||||
No | 268 | 21.54 | 12.47 | 1.49 | 0.6 | 130 | 1.89 | |||||||
(14.09–44.40) | (9.12–18.99) | (0.58–4.94) | (0.40–0.90) | (105.14–177.72) | (1.43–2.67) | |||||||||
Recur. | ||||||||||||||
Yes | 12 | 17.37 | 0.994 | 11.38 | 0.808 | 11.14 | 0.001 | 0.7 | 0.081 | 140.35 | 0.384 | 2.9 | 0.031 | |
(9.62–274.60) | (7.55–50.66) | (2.38–63.18) | (0.50–4.10) | (92.98–332.45) | (1.85–5.09) | |||||||||
No | 270 | 21.47 | 12.5 | 1.47 | 0.6 | 130.25 | 1.88 | |||||||
(14.13–41.76) | (9.10–18.83) | (0.59–4.83) | (0.40–1.00) | (105.94–177.31) | (1.42–2.67) |
P-v: p value; Type: types of endometrial carcinoma; FIGO: the FIGO stage; Grade: Histopathological grade; D-D: D dimer; PLR: platelet to lymphocyte ratio; NLR: neutrophil to lymphocyte ratio; Metas.: metastasis; Recur.: recurrence